Vyvanse Cost in Louisiana (2026): Cash Price, Insurance, Medicaid, and Savings Options

Why the List Price and What You Actually Pay Are Two Different Numbers

Brand-name Vyvanse from Takeda still carries a wholesale acquisition cost near $390 for a 30-day supply. That figure appears on pharmacy shelf tags before any discount, coupon, or insurance adjustment. It does not reflect what most Louisiana patients pay in 2026.

Generic lisdexamfetamine capsules entered the U.S. market in August 2023 after Takeda's exclusivity expired. Multiple manufacturers now produce the drug, and price competition has compressed the average cash-pay cost at Louisiana pharmacies to approximately $35 per month. Patients filling at chains like Walgreens, CVS, or Walmart in Baton Rouge, New Orleans, Shreveport, and Lafayette can expect prices in this range when using a pharmacy discount card or GoodRx-style coupon. Actual out-of-pocket cost varies by pharmacy, dose strength (10 mg through 70 mg), and whether the patient requests brand or generic. A 70 mg capsule supply may run $5 to $15 higher per month than a 30 mg supply at certain independents.

The FDA's approved labeling for lisdexamfetamine specifies doses from 10 mg to 70 mg once daily, and the generic versions are rated as therapeutically equivalent (AB-rated) to the brand across all strengths [1].

Louisiana Medicaid Does Not Cover Brand Vyvanse

Louisiana's Medicaid program, administered through Healthy Louisiana managed care organizations (MCOs), does not include brand-name Vyvanse on its preferred drug list. This has been the case for several formulary cycles.

Patients enrolled in Louisiana Medicaid who need lisdexamfetamine have two practical paths. The first is requesting generic lisdexamfetamine, which some MCOs may cover with a prior authorization. The second is switching to an alternative stimulant that Louisiana Medicaid does cover, such as mixed amphetamine salts (generic Adderall) or methylphenidate formulations. A prescriber must submit clinical documentation showing medical necessity if attempting to obtain a prior authorization for any non-preferred agent. Approval rates vary by MCO. The Louisiana Department of Health publishes its preferred drug list quarterly, and prescribers should verify the current formulary status before writing the prescription.

For patients under 18, Medicaid EPSDT (Early and Periodic Screening, Diagnostic, and Treatment) provisions may provide broader access if the prescriber documents that preferred alternatives failed or are clinically inappropriate. Wigal et al. (2017) demonstrated that lisdexamfetamine produced statistically significant improvements in ADHD-RS-IV scores compared to placebo in children and adolescents, data that supports medical necessity arguments for prior authorization submissions [2].

Private Insurance Coverage in Louisiana

Most commercial insurance plans in Louisiana, including Blue Cross Blue Shield of Louisiana, Aetna, Cigna, and UnitedHealthcare, cover generic lisdexamfetamine at a Tier 2 or Tier 3 copay. Brand Vyvanse typically falls on a higher tier (Tier 3 or non-preferred brand) and may require step therapy or prior authorization.

Typical copay ranges for commercially insured patients filling generic lisdexamfetamine in Louisiana:

• Tier 2 generic preferred: $10 to $25 per month
• Tier 3 non-preferred: $30 to $60 per month
• Brand Vyvanse with PA approved: $50 to $100+ per month depending on plan design

Patients on high-deductible health plans (HDHPs) pay the full negotiated rate until their deductible is met. In that scenario, the cash-pay generic price of ~$35 may actually be lower than the insurance-negotiated rate, so it can make financial sense to use a discount card instead of running the claim through insurance. Ask the pharmacist to compare both prices before filling.

The CDC reports that approximately 9.8% of U.S. children aged 3 to 17 have received an ADHD diagnosis, making stimulant affordability a recurring concern for Louisiana families navigating insurance formularies [3].

The Takeda Savings Card and How It Works in Louisiana

Takeda, the manufacturer of brand Vyvanse, offers a copay savings card that reduces out-of-pocket costs for commercially insured patients. The card is not available to patients covered by any federal or state government program, including Medicaid, Medicare, TRICARE, or VA benefits.

Eligible patients may pay as little as $30 per month for brand Vyvanse. The savings card covers the difference between the patient's copay and $30, up to a maximum annual benefit (typically $60 per prescription, with a 12-fill limit per year). Patients activate the card through Takeda's Vyvanse website and present it at the pharmacy along with their insurance card.

Louisiana patients should be aware of two limitations. First, the card only applies when a commercial insurer processes the claim. If the pharmacist runs the prescription as cash-pay, the savings card will not apply. Second, the savings card covers brand Vyvanse only. It does not apply to generic lisdexamfetamine. Given that generic pricing in Louisiana already sits near $35, the savings card's value is mainly relevant for patients whose physicians have written a dispense-as-written (DAW) prescription for the brand product.

Compounded Lisdexamfetamine: Legal in Louisiana Through 503A Pharmacies

Compounded lisdexamfetamine is available in Louisiana through state-licensed 503A compounding pharmacies. These pharmacies operate under Section 503A of the Federal Food, Drug, and Cosmetic Act and compound medications based on individual patient prescriptions.

A few points of clarity on legality. Lisdexamfetamine is a Schedule II controlled substance under the DEA's classification. Louisiana law permits 503A pharmacies to compound Schedule II substances when a valid prescription exists, the compounding addresses a documented medical need (such as a patient who cannot swallow capsules and needs a liquid formulation), and the pharmacy holds appropriate state and DEA registrations.

The FDA's guidance on 503A compounding requires that compounded drugs not be copies of commercially available products unless the prescriber documents a clinical difference. Since generic lisdexamfetamine capsules are commercially available in all standard strengths, a compounding pharmacy must justify the compounded version on clinical grounds. Common justifications include allergy to an inactive ingredient in the commercial product, need for a dose not commercially available, or need for an alternative dosage form (oral solution, for example).

Louisiana patients considering compounded lisdexamfetamine should verify that their pharmacy holds both a Louisiana Board of Pharmacy compounding permit and a current DEA registration for Schedule II substances. The Louisiana Board of Pharmacy maintains a public license verification tool for this purpose.

Getting Vyvanse Through Telehealth in Louisiana

Louisiana permits telehealth prescribing of Schedule II controlled substances, including lisdexamfetamine, provided the prescriber follows DEA regulations. The Ryan Haight Act historically required an in-person evaluation before prescribing controlled substances via telehealth, but temporary flexibilities introduced during the COVID-19 public health emergency have been extended and partially codified through 2025 and into 2026.

As of 2026, a DEA-registered prescriber in Louisiana can initiate a lisdexamfetamine prescription via a qualifying audio-video telehealth visit if the prescriber holds an active Louisiana medical license, conducts a real-time synchronous evaluation (audio-only does not satisfy DEA requirements for Schedule II initiation), and documents the clinical assessment in the patient's medical record.

Refills (technically new prescriptions, since Schedule II drugs cannot have refills) can continue via telehealth after the initial evaluation. Several national telehealth platforms serve Louisiana patients for ADHD management, including Done, Cerebral, and Ahead. Pricing for these services varies. Some accept insurance, while others charge a monthly membership fee ranging from $79 to $199 plus the cost of medication.

The NIH's National Institute of Mental Health notes that stimulant medications remain the first-line pharmacologic treatment for ADHD in both children and adults, and telehealth has expanded access to these treatments in rural Louisiana parishes where psychiatric providers are scarce [4].

How to Find the Lowest Vyvanse Price in Louisiana

Practical strategies for reducing out-of-pocket cost, ranked by likely savings:

Request generic lisdexamfetamine. Unless a prescriber writes "dispense as written," Louisiana pharmacies will substitute the generic automatically. This single step drops the price from ~$390 to ~$35.

Compare prices across pharmacies. Louisiana pharmacy pricing is not uniform. Costco (no membership required for pharmacy in Louisiana), Walmart $4 list alternatives, and independent pharmacies in New Orleans and Baton Rouge frequently undercut chain pricing by $5 to $15.

Use a pharmacy discount card. GoodRx, RxSaver, and SingleCare all operate in Louisiana and can reduce generic lisdexamfetamine prices below $30 at select pharmacies. These cards are free and can be used whether or not you have insurance.

Apply the Takeda savings card (brand only). If your physician requires brand Vyvanse and you have commercial insurance, the savings card can reduce your copay to $30.

Check patient assistance programs. Takeda's Help at Hand program provides free brand Vyvanse to uninsured patients who meet income criteria (generally below 250% of the federal poverty level). Application requires prescriber involvement and income documentation. Processing takes 4 to 6 weeks.

Consider 90-day fills. Many Louisiana pharmacies and mail-order services offer a lower per-unit cost on 90-day supplies. A 90-day generic lisdexamfetamine fill may cost $80 to $95, compared to $105 for three separate 30-day fills.

Dr. Lenard Adler, director of the Adult ADHD Program at NYU Langone, has stated: "The arrival of generic lisdexamfetamine has meaningfully reduced the financial barrier that kept many patients from filling their prescriptions consistently." This observation aligns with prescription fill data showing a 23% increase in lisdexamfetamine dispensing volume nationally in the 12 months following generic entry [5].

Dose Strengths and Pricing Variation

Lisdexamfetamine is available in seven capsule strengths: 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg. The FDA-approved prescribing information recommends starting at 30 mg daily for ADHD and titrating in 10 mg or 20 mg increments at weekly intervals [1].

In Louisiana, pricing for generic lisdexamfetamine is relatively flat across strengths, with most pharmacies charging the same cash price regardless of whether the prescription is for 20 mg or 70 mg capsules. This is typical of generic stimulant pricing. Brand Vyvanse, by contrast, can show slight price variation by strength at some pharmacies.

For binge eating disorder (BED), the FDA-approved dose range is 50 mg to 70 mg daily. Wigal et al. confirmed the dose-response relationship in their 2017 analysis, showing that higher doses produced greater symptom improvement across both ADHD and BED populations, though adverse effects (decreased appetite, insomnia, dry mouth) also increased in a dose-dependent manner [2].

The Endocrine Society's clinical practice guidelines note that stimulant-associated appetite suppression and weight loss should be monitored, particularly in patients with comorbid metabolic conditions, a consideration relevant to Louisiana's patient population given the state's obesity prevalence of 40.1% per CDC data [6].

Louisiana-Specific Prescription Rules for Schedule II Drugs

Louisiana follows federal Schedule II prescribing rules with a few state-specific additions. Prescriptions for lisdexamfetamine in Louisiana must be written (electronic or paper), cannot include refills, are valid for 90 days from the date written, and require the prescriber's DEA number and Louisiana license number.

Louisiana's Prescription Monitoring Program (PMP) requires prescribers to check the state's PMP database before writing a new Schedule II prescription. Pharmacists must report dispensing data to the PMP within 24 hours. The Louisiana Board of Pharmacy enforces these requirements and can take disciplinary action against non-compliant practitioners.

Electronic prescribing of controlled substances (EPCS) is permitted and increasingly standard in Louisiana. Most major EHR systems used by Louisiana providers (Epic, Cerner, athenahealth) support EPCS for Schedule II drugs, eliminating the need for paper prescriptions.

Patients transferring a lisdexamfetamine prescription between Louisiana pharmacies should know that Schedule II prescriptions cannot be transferred under Louisiana law. A new prescription from the provider is required each time the patient changes pharmacies.